We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

21 hedge funds and large institutions have $69.6M invested in Sinovac Biotech, Ltd in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $61.7M → $69.6M (+$7.91M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9% less funds holding

Funds holding: 23 → 21 (-2)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
21
Holders Change
-2
Holders Change %
-8.7%
% of All Funds
0.43%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
–
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$3.49K

Top Sellers

Rank Fund Capital Flow
1
FIM
Freedom Investment Management
Connecticut
-$419

SVA Hedge Fund Activity: Q2 2020 in Review

21 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2020, worth a combined $69.6M — up 13% from $61.7M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SVA and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $3.49K. The largest seller was Freedom Investment Management, cutting an estimated $419.

  • 21 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2020, down from 23 in Q1 2020.
  • Funds reported $69.6M of Sinovac Biotech, Ltd stock for Q2 2020, up 13% quarter-over-quarter.
  • 0 funds opened new Sinovac Biotech, Ltd positions in Q2 2020 and 2 closed out, a net change of -2 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q2 2020 was UBS Group, an estimated $3.49K added.
  • The largest Sinovac Biotech, Ltd seller in Q2 2020 was Freedom Investment Management, an estimated $419 sold.

Based on aggregated 13F filings for Q2 2020.